Who are Isovue 250's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isovue-250.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Isovue 250 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Isovue 250 (Isovue 250) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iodinated contrast medium (non-ionic). Area: Diagnostic Imaging.

marketed Iodinated contrast medium (non-ionic) Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Isovue 250 (Isovue 250) — Bracco Diagnostics, Inc. Isovue 250 is an iodinated contrast medium that increases radiodensity in blood vessels and tissues to enhance visualization during X-ray and CT imaging procedures.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Isovue 250 TARGET	Isovue 250	Bracco Diagnostics, Inc	marketed	Iodinated contrast medium (non-ionic)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iodinated contrast medium (non-ionic) class)

Bracco Diagnostics, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isovue 250 — Competitive Intelligence Brief. https://druglandscape.com/ci/isovue-250. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing